Takeda Pharmaceutical is Japan's largest pharmaceutical company and one of the top global biopharmaceutical companies by revenue. The company focuses on oncology, rare diseases, neuroscience, gastroenterology, and plasma-derived therapies, with a portfolio of innovative medicines sold in over 80 countries. Takeda significantly expanded its global scale through the acquisition of Shire in 2019. Headquartered in Tokyo with major operations in the United States, Europe, and Asia, Takeda generates the majority of its revenue outside Japan.

For international investors, Takeda Pharmaceutical is Japan's largest and most globally integrated pharmaceutical company, with a primary focus on oncology, rare diseases, neuroscience, and gastroenterology. Following its landmark acquisition of Shire, Takeda operates as a genuine global top-ten pharmaceutical company with the majority of revenues generated outside Japan. The company's innovative pipeline and established global commercial operations make it the primary vehicle for investors seeking large-cap Japanese pharmaceutical exposure with true multinational scale.

No press releases found.